Update on CheckMate 067, an advanced melanoma clinical trial

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma. This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

update, update checkmate 067, phase 3 study, nivolumab, nivolumab plus ipilimumab, ipilimumab alone, in previously untreated advanced melanoma, advanced melanoma, ncri 2015, ncri, national cancer research institute, cancer conference